Pyrimidine intermediates
Abstract
Abstract The present invention is directed to compounds of formula (I), ##STR1## wherein R 1 is OH, NH 2 ; R 2 is a heteroaromatic or aromatic substituent; R 3 is H, OH, F, OCH 3 ; R 4 is H, F, OH or an ether or ester residue thereof, OCH 3 , CN, C═CH, N 3 ; R 5 is OH or an ether or ester residue thereof including mono, di- and triphosphate esters (α), wherein n is 0 or 1 and M is hydrogen or a pharmaceutically acceptable counterion such as sodium, potassium, ammonium or alkylammonium; and pharmaceutically acceptable salts thereof; and pharmaceutical compositions comprising said compounds can be used for therapeutic treatment of virus infections. The present invention is also directed to compounds of formula (I'), ##STR2## wherein R 1 and R 2 are as defined above, as intermediates.
Inventors
- 👤 Salo Gronowitz
Bibliographic Details
Claims Analysis
Total Claims: 4References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-08-07 | 1999-02-06 | 1999-08-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-08-07 | 2003-02-06 | 2003-08-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-08-07 | 2007-02-06 | 2007-08-08 | $7700.00 | Window Closed / Lapsed |